Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market value surges as Kailera's weight-loss pill faces market setbacks despite successful clinical efficacy in China.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Kailera reported that its oral GLP-1 asset achieved an 11% weight loss and met goals in phase 3 obesity and diabetes trials in China. However, the company's shares tumbled following reports of high nausea rates associated with the drug.
Coverage from BioPharma Dive, Endpoints News, Reuters, and Fierce Biotech emphasizes the contrast between the drug's efficacy and its high side effect rates. Investor's Business Daily notes that this setback has contributed to a further increase in Eli Lilly's market capitalization.
Future developments depend on the impact of these side effect rates on Kailera's market position and the continued growth of Eli Lilly's valuation.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 54m ago.
Quick answers
What was the weight loss result in Kailera's trial?
The oral GLP-1 asset saw 11% weight loss in Chinese phase 3 obesity and diabetes trials.
Why did Kailera's shares tumble?
Shares fell due to high nausea rates despite the drug's success in the trials.
How did Eli Lilly react to these events?
According to Investor's Business Daily, Eli Lilly's market capitalization increased.
Coverage (5)
- Kailera says obesity pill succeeds in late-stage trial in China BioPharma Dive · 5h ago
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials Endpoints News · 5h ago
- Kailera shares tumble on high nausea rates despite weight-loss drug's success Reuters · 5h ago
- Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials Fierce Biotech · 5h ago
- Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback Investor's Business Daily · 5h ago
Topics
Related trends
Wegovy weight loss pill now available in UK
The UK has launched the first daily oral GLP-1 weight management pill, Wegovy, now available via high street and online pharmacies.
Tornadoes and storms in central China kill at least 11 people
Severe tornadoes and storms in central China have resulted in at least 11 deaths amid a week of unusual global weather patterns.
How easy is it to get weight-loss drugs online? Secret shoppers from Yale found out.
A Yale secret shopper study reveals significant gaps in the online prescribing process for GLP-1 obesity medications.
Chinese AI models are gaining ground with U.S. companies as OpenAI, Anthropic costs surge
U.S. companies are increasingly adopting Chinese AI models as costs for OpenAI and Anthropic rise.
EXCLUSIVE: Beijing is looking at curbing overseas access to China's top AI models, sources say
Beijing is reportedly considering restrictions on how users outside of China access the country's most advanced AI models.
China Reports 10 Dead After Rain and Storms Batter Provinces
Severe storms, tornadoes, and landslides across China have resulted in multiple fatalities as Typhoon Bavi looms offshore.